Chemomab Therapeutics (CMMB) EBIT (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported EBIT for 9 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 5.25% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $7.6 million (down 36.13% YoY), and the FY2025 full-year result was $9.0 million, down 35.5% from the prior year.
• EBIT advanced to $2.2 million in Q2 2026 per CMMB's latest filing, from $1.8 million in the prior quarter.
• Across five years, EBIT topped out at $8.7 million in Q1 2023 and bottomed at -$5.1 million in Q1 2022.
• Historically, EBIT has averaged $3.8 million across 5 years, with a median of $3.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBIT jumped 364.25% in 2022, then tumbled 62.12% in 2023.
• Over 5 years, EBIT stood at $7.9 million in 2022, then sank by 62.12% to $3.0 million in 2023, then retreated by 0.77% to $3.0 million in 2024, then slumped by 36.79% to $1.9 million in 2025, then advanced by 15.59% to $2.2 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered $2.2 million, $1.8 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.